A new research study has shown that pancreatic cancer cells can be coaxed to revert back toward normal cells by introducing a protein called E47.
E47 binds to specific DNA sequences and controls genes involved in growth and differentiation. The research provides hope for a new treatment approach for the more than 40,000 people who die from the disease each year in the United States.
“For the first time, we have shown that overexpression of a single gene can reduce the tumor-promoting potential of pancreatic adenocarcinoma cells and reprogram them toward their original cell type. Thus, pancreatic cancer cells retain a genetic memory which we hope to exploit,” said Pamela Itkin-Ansari, Ph.D., adjunct professor in the Development, Aging, and Regeneration Program at Sanford-Burnham and lead author of the study published today in the journal Pancreas.
E47 turns the clock back
The study, a collaborative effort between Sanford-Burnham, UC San Diego, where Itkin-Ansari holds a joint appointment, and Purdue University, generated human pancreatic ductal adenocarcinoma cell lines to make higher-than-normal levels of E47. The increased amount of E47 caused cells to stall in the G0/G1 growth phase, and differentiate back toward an acinar cell phenotype.
In-vivo studies showed that when the reprogrammed cancer cells were introduced into mice, their ability to form tumors was greatly diminished compared to untreated adenocarcinoma cells.
“Presently, pancreatic adenocarcinoma is treated with cytotoxic agents, yet the average survival for patients post-diagnosis is merely six months, and the improvements in therapies are measured in days,” said Andrew M. Lowy, M.D., professor of surgery at the UC San Diego Moores Cancer Center and co-chair of the National Cancer Institute’s Pancreatic Cancer Task Force. “The finding that we can differentiate these cancer cells back to a non-threatening phenotype is encouraging. Indeed, there is a precedent for cell differentiation therapy in that the approach has been used to treat acute promyelocytic leukemia (APL) and some neuroblastomas successfully.”
“Our next step is to test primary patient-derived tumor tissue to determine whether E47 can produce similar results, potentially providing a novel therapeutic approach to combating this highly lethal disease,” said Itkin-Ansari. “Additionally, we are screening for molecules—potential drugs—that can induce overexpression of E47.”
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Pet supply stores band together to help Oakland County deputy battling canceron April 14, 2021 at 4:12 pm
It’s been a tough year for all of us but for Oakland County Sheriff’s deputy Bob Loken, it’s been extra hard as he was diagnosed with pancreatic cancer last fall.
- This One Thing Wards Off "Deadly" Prostate Cancer, New Study Findson April 14, 2021 at 6:46 am
Signs You're Getting One of the Supreme Court Justice Ruth Bader Ginsburg died from complications of metastatic pancreatic cancer. The same deadly disease took civil rights leader and Democratic ...
- Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technologyon April 14, 2021 at 5:06 am
SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) On April 7, 2021 Oncology Pharma, Inc. (the “Company”) reported that it had been granted an exclusive worldwide ...
- Dannielle Engle awarded prestigious pancreatic cancer research granton April 13, 2021 at 9:00 pm
Salk Assistant Professor Dannielle Engle was selected as the first recipient of the Lustgarten Foundation-AACR Career Development Award for Pancreatic Cancer Research in Honor of Ruth Bader Ginsburg, ...
- Is There A Link Between Pancreatic Cancer And Diabetes After Age 50? Pancreatic Cancer Action Network Launches $25 Million, Large-Scale Studyon April 13, 2021 at 5:16 am
The Pancreatic Cancer Action Network (PanCAN) is taking an ambitious step forward today in the race to detect pancreatic cancer early. It launched its Early Detection Initiative, the largest ...
- Role of stromal activin A in human pancreatic cancer and metastasis in miceon April 12, 2021 at 5:35 am
Pancreatic ductal adenocarcinoma (PDAC) has extensive stromal involvement and remains one of the cancers with the highest mortality rates. Activin A has been implicated in colon cancer and its stroma ...
- CD40 drug before surgery can benefit patients with early-stage pancreatic canceron April 11, 2021 at 9:44 pm
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, ...
- Mutant KRAS and P53 promote growth and metastasis of pancreatic canceron April 11, 2021 at 9:36 pm
Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein to ...
- After Losing Our Dad to Pancreatic Cancer, We Got Genetic Testingon April 10, 2021 at 8:00 am
Editor’s note: Before Melissa Soukup joined PanCAN as a full-time staff member, she and her sisters were dedicated volunteers – because they lost their father to pancreatic cancer in 2011. Melissa, ...
- Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasison April 9, 2021 at 9:00 pm
MD Anderson researchers have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact to promote metastasis and tumor growth. The findings point to a new ...
via Bing News